GlassScriptPhysician profile
Marjorie T Daoud
NPI 1346276995
$1,253.99
in general payments reported to CMS, 2019-2025
11 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $167 · 2021: $105 · 2022: $152 · 2023: $232 · 2024: $282 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.47 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Viiv Healthcare Company | $223.54 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $174.60 | 2021-2025 | Dificid, Zerbaxa, Recarbrio |
| Astellas Pharma US INC | $141.46 | 2019-2021 | |
| Allergan, INC. | $127.71 | 2019-2020 | |
| Insmed, INC. | $50.04 | 2022-2024 | Arikayce |
| Janssen Biotech, INC. | $40.74 | 2019-2023 | Symtuza |
| Mayne Pharma Commercial LLC | $27.01 | 2019-2020 | |
| Exact Sciences Corporation | $17.03 | 2025 | Cologuard Collection Kit |
| Emd Serono, INC. | $15.25 | 2024 | |
| Gilead Sciences, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.